Parkinson's Disease News and Research

Latest Parkinson's Disease News and Research

BrainStorm provides review of recent accomplishments for shareholders, investors

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies and therapeutics, today provided a review of recent accomplishments for shareholders and investors.

25 Mar 2011

Dopamine agonists used in treatment of Parkinson's disease may lead to impulse control disorders

Mayo Clinic researchers found that dopamine agonists used in treating Parkinson's disease result in impulse control disorders in as many as 22 percent of patients.

24 Mar 2011

Rexahn completes 33% of 300 patient enrollment in Serdaxin Phase IIb clinical trial for major depressive disorder

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has enrolled 33 percent of the total projected patients required for its Phase IIb clinical trial of Serdaxin to treat major depressive disorder (MDD).

24 Mar 2011

Mayo Clinic receives $1 million gift for Lewy body dementia study

To help continue its internationally recognized work in Lewy body dementia, the Harry T. Mangurian, Jr., Foundation has awarded Mayo Clinic a $1 million gift, pledged over four years. Lewy body dementia, which combines aspects of both Alzheimer's and Parkinson's diseases, is the second most common form of dementia in the United States.

23 Mar 2011

Study: Stem cell transplant may benefit patients with rapidly progressive MS

A long term study reports about the effectiveness of replacing bone marrow, purposely destroyed by chemotherapy, with autologous stem cell rescue for people with aggressive forms of multiple sclerosis.

22 Mar 2011

‘Sleeping sickness’ pandemic offers insight into Parkinson’s

A bizarre disease that caused sufferers to fall into a deep ‘sleep’ while still being aware of their surroundings can offer us insight into the nature of Parkinson’s disease.

21 Mar 2011

XenoPort reports preliminary top-line results from arbaclofen placarbil Phase 2b clinical trial in GERD

XenoPort, Inc. announced today preliminary top-line results from a Phase 2b clinical trial of arbaclofen placarbil (also known as AP) as adjunctive therapy in patients with gastroesophageal reflux disease (GERD) who do not experience complete relief of GERD symptoms while being treated with proton pump inhibitors (PPI).

21 Mar 2011

More opportunities to develop therapies for protein misfolding

Romping clumps of misfolded proteins are prime suspects in many neurological disorders including Alzheimer's, Parkinson's, and Creutzfeld-Jakob Disease. Those diseases are devastating and incurable, but a team of biologists at Brown University reports that cells can fix the problems themselves with only a little bit of help. The insight suggests that there are more opportunities to develop a therapy for protein misfolding than scientists had thought.

21 Mar 2011

Drug delivery breakthrough for Alzheimer’s disease

Till date all attempts to get drugs into the brain were countered by the blood-brain barrier - the natural defense against potentially harmful chemicals floating around the body. However this new finding from a team from University of Oxford shows that now scientists have successfully switched off a gene implicated in Alzheimer’s disease in the brains of mice by exploiting tiny particles naturally released by cells, called exosomes.

21 Mar 2011

Cortex reports net loss of $0.01 per share for quarter ended December 31, 2010

Cortex Pharmaceuticals, Inc. reported a net loss applicable to common stock of $984,000, or $0.01 per share for the quarter ended December 31, 2010 compared with a net loss of $1,599,000, or $0.02 per share for the corresponding prior year period.

18 Mar 2011

Researchers discover a type of 'cellular bilingualism' in brain

A team of researchers from the University of Montreal and McGill University have discovered a type of "cellular bilingualism" - a phenomenon that allows a single neuron to use two different methods of communication to exchange information.

18 Mar 2011

Gene therapy for Parkinson’s: It works!

A latest study has shown that gene therapy may be successful in treating the dreaded brain degenerative disease – Parkinson’s disease. Neurologists are hopeful that it could be useful in other neurologic disorders too.

17 Mar 2011

Low calorie diet may delay or prevent aging and neurodegenerative diseases

Cells, which employ a process called autophagy to clean up and reuse protein debris leftover from biological processes, were the original recyclers. A team of scientists from Paul Greengard's Rockefeller University laboratory have linked a molecule that stimulates autophagy with the reduction of one of Alzheimer's disease's major hallmarks, amyloid peptide.

17 Mar 2011

Experts to review latest research on bariatric surgery at International summit

On March 28, leading experts across multiple disciplines will convene at the 2nd World Congress on Interventional Therapies for Type 2 Diabetes to review the latest research on bariatric surgery as a treatment option.

17 Mar 2011

New study: Positive outcomes from gene therapy trial in patients with Parkinson's

A multi-center gene therapy trial for patients with advanced Parkinson's disease demonstrated reduced symptoms of the progressive movement disorder, according to a new study published in Lancet Neurology.

17 Mar 2011

65-year-old woman receives new neurostimulator implant for deep brain stimulation therapy

A 65-year-old woman with Parkinson's disease became the first patient in the United States to receive a new device for deep brain stimulation (DBS) therapy.

17 Mar 2011

Gene therapy holds promise for Parkinson's treatment

A first-of-its-kind study of gene therapy in the treatment of Parkinson's disease determined that half of all patients who received the treatment had "clinically meaningful improvements" of their symptoms within six months of surgery.

17 Mar 2011

The Lancet Neurology publishes Neurologix NLX-P101 Phase 2 trial results against PD

Neurologix, Inc., announced today that the results of the Company's Phase 2 clinical trial for its novel, investigational gene therapy NLX-P101 for the treatment of Parkinson's disease were published in an online-first edition of The Lancet Neurology.

17 Mar 2011

Medtronic introduces Activa SC deep brain stimulation system in the U.S. and Europe

With the first U.S. implant of its new Activa SC neurostimulator for deep brain stimulation therapy, Medtronic, Inc. today announced the technology's commercial availability throughout the United States and Europe.

17 Mar 2011

Results from first successful phase 2 trial of gene therapy for Parkinson's or any neurologic disorder

A gene therapy called NLX-P101 dramatically reduces movement impairment in Parkinson's patients, according to results of a Phase 2 study published today in the journal Lancet Neurology. The approach introduces a gene into the brain to normalize chemical signaling.

16 Mar 2011

Parkinson's Disease News and Research

Latest Parkinson's Disease News and Research

BrainStorm provides review of recent accomplishments for shareholders, investors

Dopamine agonists used in treatment of Parkinson's disease may lead to impulse control disorders

Rexahn completes 33% of 300 patient enrollment in Serdaxin Phase IIb clinical trial for major depressive disorder

Mayo Clinic receives $1 million gift for Lewy body dementia study

Study: Stem cell transplant may benefit patients with rapidly progressive MS

‘Sleeping sickness’ pandemic offers insight into Parkinson’s

XenoPort reports preliminary top-line results from arbaclofen placarbil Phase 2b clinical trial in GERD

More opportunities to develop therapies for protein misfolding

Drug delivery breakthrough for Alzheimer’s disease

Cortex reports net loss of $0.01 per share for quarter ended December 31, 2010

Researchers discover a type of 'cellular bilingualism' in brain

Gene therapy for Parkinson’s: It works!

Low calorie diet may delay or prevent aging and neurodegenerative diseases

Experts to review latest research on bariatric surgery at International summit

New study: Positive outcomes from gene therapy trial in patients with Parkinson's

65-year-old woman receives new neurostimulator implant for deep brain stimulation therapy

Gene therapy holds promise for Parkinson's treatment

The Lancet Neurology publishes Neurologix NLX-P101 Phase 2 trial results against PD

Medtronic introduces Activa SC deep brain stimulation system in the U.S. and Europe

Results from first successful phase 2 trial of gene therapy for Parkinson's or any neurologic disorder

eBook: Advancing neurodegenerative research with iPSC-derived microglia models eBook

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Parkinson's Disease News and Research

Latest Parkinson's Disease News and Research

eBook: Advancing neurodegenerative research with iPSC-derived microglia models eBook

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in